Product Program year 2021 Source: CMS Open Payments

In-vitro diagnostic reagents

Device In-vitro diagnostic reagents

Open in the dashboard

General payments

$2,450,275

6 payments

Research payments

$106,596

5 payments

Through program year 2021, $2,450,275 in general payments and $106,596 in research payments were reported against In-vitro diagnostic reagents (In-vitro diagnostic reagents).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2021 General $2,450,275 6
2021 Research $106,596 5

Breakdown

Who paid General payments · program year 2021
  1. Fujirebio Diagnostics, Incorporated $2,450,275 6 payments
Top recipients General payments · program year 2021
  1. Dana-Farber Cancer Institute Teaching hospital · MA $2,133,635 87% · 1 payment
  2. University Of Washington Med Ctr Teaching hospital · WA $180,000 7% · 1 payment
  3. Milton S. Hershey Medical Center Teaching hospital · PA $125,082 5% · 1 payment
  4. Richard Moore Gynecologic Oncology · Rochester, NY $6,000 <1% · 1 payment
  5. Christopher Defilippi Cardiovascular Disease · Baltimore, MD $3,300 <1% · 1 payment

The top 5 of 6 recipients; each share is of general payments naming this product in 2021.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2021
  1. Gynecologic Oncology Obstetrics & Gynecology $6,000 52% · 1 practitioner
  2. Cardiovascular Disease Internal Medicine $3,300 29% · 1 practitioner
  3. Hematology & Oncology Internal Medicine $2,258 20% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2021
  1. Massachusetts $2,133,635 87% · 1 recipient
  2. Washington $180,000 7% · 1 recipient
  3. Pennsylvania $125,082 5% · 1 recipient
  4. New York $6,000 <1% · 1 recipient
  5. Maryland $3,300 <1% · 1 recipient

The top 5 of 6 states; each share is of general payments naming this product in 2021 where a state was reported.

The top 25 states, free in the app

6 general · 5 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record